Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name BGB-283
Trade Name
Synonyms Lifirafenib
Drug Descriptions

Lifirafenib (BGB-283) is a dual RAF kinase and EGFR inhibitor, which may lead to decreased tumor cell proliferation and reduced growth of tumors with activation of BRAF and/or EGFR (PMID: 26208524, PMID: 32182156).

DrugClasses BRAF Inhibitor 20 EGFR Inhibitor (Pan) 52
CAS Registry Number 1446090-79-4
NCIT ID C124995

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
BGB-283 BGB-283 10 1
BGB-283 + Cetuximab BGB-283 Cetuximab 1 0
BGB-283 + MK-8353 BGB-283 MK-8353 2 0
BGB-283 + PD-0325901 BGB-283 PD-0325901 0 1
BGB-283 + SCH772984 BGB-283 SCH772984 3 0
BGB-283 + Trametinib BGB-283 Trametinib 4 0
BGB-283 + Ulixertinib BGB-283 Ulixertinib 2 0
BGB-283 + Vemurafenib BGB-283 Vemurafenib 2 0


Additional content available in CKB BOOST